Arbutus Biopharma Corpora... (ABUS)
NASDAQ: ABUS
· Real-Time Price · USD
3.46
-0.12 (-3.35%)
At close: Jun 17, 2025, 3:59 PM
3.55
2.60%
After-hours: Jun 17, 2025, 07:49 PM EDT
-3.35% (1D)
| Bid | 3.33 |
| Market Cap | 662.68M |
| Revenue (ttm) | 6.4M |
| Net Income (ttm) | -76.57M |
| EPS (ttm) | -0.41 |
| PE Ratio (ttm) | -8.44 |
| Forward PE | -17.92 |
| Analyst | Buy |
| Ask | 3.72 |
| Volume | 555,580 |
| Avg. Volume (20D) | 931,038 |
| Open | 3.55 |
| Previous Close | 3.58 |
| Day's Range | 3.45 - 3.56 |
| 52-Week Range | 2.71 - 4.72 |
| Beta | 1.24 |
About ABUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-0.9%
ABUS stock has given up its prior gain. Arbutus Bi...
Unlock content with
Pro Subscription
1 month ago
-0.9%
Arbutus Biopharma shares are trading higher after the company presented clinical trial data from its two HBV assets.
